NFKB1 and asthma: Although inhibitors that target activation of NF-κB have been shown to suppress certain synthetic functions of ASM172 and modulate pro-inflammatory outcomes in epithelial cells173, specific NF-κB inhibitors have not translated into clinical trials for asthma and this is due to their multiple side effects129.